Patents for A61P 35 - Antineoplastic agents (221,099)
04/2003
04/23/2003CN1413249A Human heparanase-related polypeptide and nucleic acid
04/23/2003CN1413230A Highly-neutralized ethylene copolymers and their use in golf balls
04/23/2003CN1413220A Anti-prostate stem cell antigen (PSCA) antibody compositions and method of use
04/23/2003CN1413213A Azaindoles
04/23/2003CN1413211A Substituted 1,3,4-oxadiazoles and method of producing TNF-alpha levels
04/23/2003CN1413207A 5-membered ring heterocyclic compounds with nitrogen
04/23/2003CN1413206A Non peptide tachykinin receptor antagonists
04/23/2003CN1413205A 2-(1H-indol-3-yl)-2-oxo-acetamides with antitumor activity
04/23/2003CN1413204A Method for producing therapeutic agents for ulcers
04/23/2003CN1413198A Methods and compositions utilizing quianzolinones
04/23/2003CN1413193A Nitrile derivatives as cathepsin K inhibitors
04/23/2003CN1413181A Novel hydronaphtalene compounds prepared by phodium catalyzed ring opening reaction in presence of phosphine ligand
04/23/2003CN1413118A Liquid composition of biodegradable block copolymer for drug delivery system and process for preparation thereof
04/23/2003CN1413109A Substituted acylhydroxamic acids and method of reducing TNF-alpha levels
04/23/2003CN1413107A Use of hypoglycemic agent for treating impaired clucose metabolism
04/23/2003CN1413105A Novel method of treatment
04/23/2003CN1412313A Expression of recombinant human troponin I in colibacillus and its application for resisting tumor
04/23/2003CN1412312A Expression of recombinant human quick skeletal muscle type troponin C in colibacillus and its application for resisting tumor
04/23/2003CN1412297A Fermentation method of engineering bacterium for producing anti-cacer medicine
04/23/2003CN1412295A Oncolytic microorganism expressing heat shock protein and its application
04/23/2003CN1412201A Monoclonal antibody for resisting human liver cancer and its application
04/23/2003CN1412187A Nicotinamidobenzozine and its application
04/23/2003CN1412181A Carboxylic acid derivative capable of inhibiting combination of integrin and its receptor
04/23/2003CN1411853A Medicine for curing osteosarcoma and its preparation method
04/23/2003CN1411813A Theobromine with anticancer activity
04/23/2003CN1411809A Usage and composition of pyridine onium derivative for curing application
04/23/2003CN1411800A Cosmetic composition and method
04/23/2003CN1106384C Indoline-2-one derivatives, its preparing method and its medicinal compositions
04/23/2003CN1106199C Pure Chinese medicine anti-tumour medicine and its preparing process
04/22/2003USRE38090 Antitumor activity; useful for treatment and prevention of cancers
04/22/2003US6552223 N-hydroxacylamino compounds, process for their preparation and pharmaceutical compositions containing them
04/22/2003US6552202 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
04/22/2003US6552192 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof
04/22/2003US6552183 Moncyclic L-nucleosides analogs
04/22/2003US6552180 Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-2 and uses thereof
04/22/2003US6552166 Process for the preparation of conjugates useful in the treatment of prostate cancer
04/22/2003US6552076 Anticarcinogenic agents; controlling apoptosis
04/22/2003US6552075 Therapeutic compounds and methods of use
04/22/2003US6552073 Compounds and methods of treating cell proliferative diseases
04/22/2003US6552069 3-methyl-chroman and -thiochroman derivatives
04/22/2003US6552068 Having anti-estrogenic activity; for use in therapy
04/22/2003US6552043 Benzimidazolinyl piperidines as CGRP ligands
04/22/2003US6552030 Inhibit human factor Xa; treating thrombotic activity; 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((2-(1,2 -dihydoxyethyl)-4-hydroxy-5-ethoxytetrahydrofuran-3-yl)oxy)-pyridin-2 -yl)oxy)4-hydroxybenzamidine
04/22/2003US6552027 4-((3-hydroxyphenyl)amino),6,7-dimethoxy-quinazoline for example; conjugates with epidermal growth factor
04/22/2003US6552019 Inhibitors of p38
04/22/2003US6551823 EBV-infected stomach cancer cell line
04/22/2003US6551822 NL4 tie ligand homologue
04/22/2003US6551810 Polypeptide retains the ability to dephosphorylate an activated MAP-kinase
04/22/2003US6551620 Pellet formulation for the treatment of the intestinal tract
04/22/2003US6551592 Bind at the same time to the T-cell receptor complex, to tumour- associated antigens on a tumour cell, and, via the Fc portion of the bispecific antibody
04/22/2003US6551588 Administering at or around the solid tumor an expressible nucleic acid encoding interleukin-3, and providing a tumor antigen, then treating the tumor with radiotherapy
04/22/2003US6551587 Tissue-specific taanscriptional regulatory sequence operably linked to the coding region of a gene that is essential for replication of said vector.
04/22/2003CA2253869C Substituted oxobutyric acids as matrix metalloprotease inhibitors
04/22/2003CA2239187C Inhibitors of farnesyl protein transferase
04/22/2003CA2152941C Cytopathic viruses for therapy and prophylaxis of neoplasia
04/22/2003CA2102623C Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
04/19/2003CA2408797A1 Treatment of breast cancer
04/19/2003CA2361863A1 Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications
04/17/2003WO2003031969A1 Novel method of assaying immune activity
04/17/2003WO2003031940A2 Structural and cytoskeleton-associated proteins
04/17/2003WO2003031939A2 Protein modification and maintenance molecules
04/17/2003WO2003031930A2 A phosphatase associated with metastasis
04/17/2003WO2003031628A1 Secretory polypeptides having sphingosine kinase activity and sphingosine kinase genes encoding the same
04/17/2003WO2003031627A1 Platelet-origin polypeptides having sphingosine kinase activity and sphingosine kinase genes encoding the same
04/17/2003WO2003031615A1 Lysophosphatidic acid synthase inhibitor
04/17/2003WO2003031606A2 Crystal structure of an aurora kinase catalytic domain, and use thereof
04/17/2003WO2003031602A1 The oncolytic microorganisms expressing hsp and uses thereof
04/17/2003WO2003031599A2 Live attenuated salmonella strains for producing vaccines
04/17/2003WO2003031595A2 Molecules for disease detection and treatment
04/17/2003WO2003031578A2 Mammalian c-type lectins
04/17/2003WO2003031568A2 Intracellular signaling molecules
04/17/2003WO2003031475A2 Antibodies against kdr, their production and uses
04/17/2003WO2003031467A2 Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
04/17/2003WO2003031464A2 Remodeling and glycoconjugation of peptides
04/17/2003WO2003031447A2 Pyrimidine derivatives
04/17/2003WO2003031444A1 Polycyclic compounds having anti-tumor activity
04/17/2003WO2003031442A1 Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
04/17/2003WO2003031440A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists
04/17/2003WO2003031438A1 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
04/17/2003WO2003031434A1 Compounds and methods
04/17/2003WO2003031432A1 Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
04/17/2003WO2003031407A2 β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
04/17/2003WO2003031405A2 Methods for the synthesis of substituted purines
04/17/2003WO2003031404A2 Processes for the preparation of substituted isoxazoles and 2-isoxazolines
04/17/2003WO2003031400A1 Low-calcemic oxime analogs of 1alpha, 25-dihydroxy vitamin d3
04/17/2003WO2003031398A1 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor
04/17/2003WO2003031397A1 Acylsulfonamides as inhibitors of steroid sulfatase
04/17/2003WO2003031396A1 Salts of guanidine derivatives and pharmaceutical preparations consisting thereof
04/17/2003WO2003031381A2 Synthesis of (z)-3,5,4'-trimethoxystilbene, and use thereof
04/17/2003WO2003030993A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors
04/17/2003WO2003030941A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound
04/17/2003WO2003030938A1 Immunotherapeutics for cancer
04/17/2003WO2003030937A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
04/17/2003WO2003030934A2 Cpg formulations and related methods
04/17/2003WO2003030930A1 Human 3 relaxin
04/17/2003WO2003030929A1 Combination therapies using methyl donors or methyl donor enhancers and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
04/17/2003WO2003030922A2 Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis
04/17/2003WO2003030921A1 Methods for producing agrimonia extract with improved activity against hepatitis B virus and pharmaceutical and food compositions containing said extract
04/17/2003WO2003030915A1 Use of solamargine for treating skin tumors
04/17/2003WO2003030911A1 Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus